- OrganaBio has acquired substantially all operating assets of Excellos to establish a bicoastal cell therapy contract development and manufacturing organization.
- The transaction expands OrganaBio’s manufacturing footprint across the U.S. and adds San Diego-based GMP cell therapy manufacturing capabilities.
OrganaBio has acquired substantially all of the operating assets of Excellos Inc., expanding its cell therapy manufacturing operations and establishing a bicoastal contract development and manufacturing organization focused on GMP cell and blood product services.
Under the transaction, newly formed subsidiary Excellos Labs, LLC will oversee operations in San Diego. The companies stated that the acquisition combines complementary capabilities across cell isolation, cryopreservation, process development, analytical testing, and autologous and allogeneic cell therapy manufacturing.
OrganaBio said its expanded platform now includes facilities across the United States, including operations in Miami, San Francisco, Irvine, and San Diego. The San Diego site adds five ISO 7 cGMP cleanroom suites supporting cell therapy manufacturing, fill-finish activities, and cell expansion services. The company also confirmed that the existing Excellos team has been retained to support continuity for customer programs.
“Cell therapy developers and the patients waiting on their programs need a manufacturing partner that can match the pace and quality of their work. Combining OrganaBio’s and Excellos’ infrastructure and teams lets us do that more reliably than either company could alone.”
Justin Irizarry, Chief Executive Officer of OrganaBio
The combined organization said it supports therapeutic programs focused primarily on oncology and autoimmune diseases across autologous and allogeneic cell therapy development. OrganaBio added that the acquisition strengthens its CDMO and contract manufacturing capabilities by offering bicoastal GMP manufacturing, PBMC isolation, and cryopreservation services under a unified quality framework. Financial terms of the transaction were not disclosed.
